doi: 10.1073/pnas.96.10.5774.
Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism
Affiliations
- PMID:10318960
- PMCID: PMC21936
- DOI: 10.1073/pnas.96.10.5774
Item in Clipboard
Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism
A S Mandir et al. Proc Natl Acad Sci U S A..
Display options
Format
Display options
Format
Abstract
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is a neurotoxin that causes parkinsonism in humans and nonhuman animals, and its use has led to greater understanding of the pathogenesis of Parkinson's disease. However, its molecular targets have not been defined. We show that mice lacking the gene for poly(ADP-ribose) polymerase (PARP), which catalyzes the attachment of ADP ribose units from NAD to nuclear proteins after DNA damage, are dramatically spared from MPTP neurotoxicity. MPTP potently activates PARP exclusively in vulnerable dopamine containing neurons of the substantia nigra. MPTP elicits a novel pattern of poly(ADP-ribosyl)ation of nuclear proteins that completely depends on neuronally derived nitric oxide. Thus, NO, DNA damage, and PARP activation play a critical role in MPTP-induced parkinsonism and suggest that inhibitors of PARP may have protective benefit in the treatment of Parkinson's disease.
Figures
PARP−/− mice are resistant to the toxic effects of MPTP. HPLC with electrochemical detection of DA and metabolites, HVA and DOPAC, 1 week after MPTP administration. All animals are on a pure genetic background of 129 SvEv. No differences in striatal DA or metabolite content was observed in WT orPARP−/− animals after saline injection, and these values are graphically combined (n = 10). WT animals (n = 8) injected with MPTP (20 mg/kg ×4) have significant reductions in DA and metabolites compared with saline controls andPARP−/− (n = 5). Two-way ANOVA,P < 0.004 for DA, HVA, and DOPAC. Student-Newman-Keuls post hoc analysis, ∗,P < 0.05 WT MPTP vs. saline,†,P < 0.05 WT MPTP vs.PARP−/− MPTP.
DA neurons fromPARP−/− mice are resistant to MPTP neurotoxicity. TH immunostaining of representative midbrain sections 7 days after MPTP adminstration from (A) saline-injected WT, (B) saline-injectedPARP−/−, (C) MPTP-injected WT, and (D) MPTP-injectedPARP−/− mice. (E) A significant reduction of TH-immunopositive neurons is seen in the WT mice receiving MPTP (n = 5) compared with saline controls (n = 8) (∗, ANOVA with Fisher post hoc,P < 0.0001 WT MPTP vs. saline). No statistical difference is seen between saline controls andPARP−/− (n = 4) 1 week after MPTP administration (ANOVA). Counts of Nissl-stained neurons in midbrain yielded similar results (data not shown).
MPTP induces marked levels of poly(ADP-ribosyl)ation of nuclear proteins. Immunoblot analysis with mAb to poly(ADP-ribose). (A) No evidence of poly(ADP-ribosyl)ation is seen until after the fourth injection of MPTP. Polymer formation peaked at 2 hr after the fourth dose and is still detectable at 72 hr. (B) No polymer formation is seen inPARP−/− ornNOS−/− mice. No polymer formation is seen in the striata of WT animals after MPTP (not shown). P,PARP−/−; N,nNOS−/−; 3rd, time at the third injection of MPTP; h, hours after the fourth dose of MPTP; +Cont, sonicated Hela cells plus NAD as a positive control. This experiment has been replicated three times with similar results.
PARP is activated in DA neurons after MPTP intoxication. Immunohistochemical staining with an anti-poly(ADP-ribose) antibody (pseudocolored in red) in the ventral midbrain. (A) WT after MPTP delivery demonstrates intense and specific staining of DA neurons. (B)PARP−/− midbrains are devoid of immunostaining. (C)nNOS−/− mice lack poly(ADP-ribose) formation after MPTP. Poly(ADP-ribose) is not detectable in saline-injected animals (data not shown). These images were obtained from animals 4 hr after the fourth injection of MPTP. These experiments have been replicated three times with similar results.
Similar articles
- Decreases in mouse brain NAD+ and ATP induced by 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP): prevention by the poly(ADP-ribose) polymerase inhibitor, benzamide.Cosi C, Marien M.Cosi C, et al.Brain Res. 1998 Oct 26;809(1):58-67. doi: 10.1016/s0006-8993(98)00829-4.Brain Res. 1998.PMID:9795136
- Implication of poly (ADP-ribose) polymerase (PARP) in neurodegeneration and brain energy metabolism. Decreases in mouse brain NAD+ and ATP caused by MPTP are prevented by the PARP inhibitor benzamide.Cosi C, Marien M.Cosi C, et al.Ann N Y Acad Sci. 1999;890:227-39. doi: 10.1111/j.1749-6632.1999.tb07998.x.Ann N Y Acad Sci. 1999.PMID:10668429
- Poly(ADP-ribose)polymerase inhibitor can attenuate the neuronal death after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice.Yokoyama H, Kuroiwa H, Tsukada T, Uchida H, Kato H, Araki T.Yokoyama H, et al.J Neurosci Res. 2010 May 15;88(7):1522-36. doi: 10.1002/jnr.22310.J Neurosci Res. 2010.PMID:19998477
- Apoptosis inducing factor and PARP-mediated injury in the MPTP mouse model of Parkinson's disease.Wang H, Shimoji M, Yu SW, Dawson TM, Dawson VL.Wang H, et al.Ann N Y Acad Sci. 2003 Jun;991:132-9. doi: 10.1111/j.1749-6632.2003.tb07471.x.Ann N Y Acad Sci. 2003.PMID:12846982Review.
- Poly(ADP-Ribose) polymerase-1 in acute neuronal death and inflammation: a strategy for neuroprotection.Skaper SD.Skaper SD.Ann N Y Acad Sci. 2003 May;993:217-28; discussion 287-8. doi: 10.1111/j.1749-6632.2003.tb07532.x.Ann N Y Acad Sci. 2003.PMID:12853316Review.
Cited by
- NAD+ homeostasis in human health and disease.Zapata-Pérez R, Wanders RJA, van Karnebeek CDM, Houtkooper RH.Zapata-Pérez R, et al.EMBO Mol Med. 2021 Jul 7;13(7):e13943. doi: 10.15252/emmm.202113943. Epub 2021 May 27.EMBO Mol Med. 2021.PMID:34041853Free PMC article.Review.
- Small peptide inhibitor of JNK3 protects dopaminergic neurons from MPTP induced injury via inhibiting the ASK1-JNK3 signaling pathway.Pan J, Li H, Zhang B, Xiong R, Zhang Y, Kang WY, Chen W, Zhao ZB, Chen SD.Pan J, et al.PLoS One. 2015 Apr 9;10(4):e0119204. doi: 10.1371/journal.pone.0119204. eCollection 2015.PLoS One. 2015.PMID:25856433Free PMC article.
- Loss of locus coeruleus neurons and reduced startle in parkin null mice.Von Coelln R, Thomas B, Savitt JM, Lim KL, Sasaki M, Hess EJ, Dawson VL, Dawson TM.Von Coelln R, et al.Proc Natl Acad Sci U S A. 2004 Jul 20;101(29):10744-9. doi: 10.1073/pnas.0401297101. Epub 2004 Jul 12.Proc Natl Acad Sci U S A. 2004.PMID:15249681Free PMC article.
- PARP-1 modulates amyloid beta peptide-induced neuronal damage.Martire S, Fuso A, Rotili D, Tempera I, Giordano C, De Zottis I, Muzi A, Vernole P, Graziani G, Lococo E, Faraldi M, Maras B, Scarpa S, Mosca L, d'Erme M.Martire S, et al.PLoS One. 2013 Sep 24;8(9):e72169. doi: 10.1371/journal.pone.0072169. eCollection 2013.PLoS One. 2013.PMID:24086258Free PMC article.
- Niacin metabolism and Parkinson's disease.Fukushima T.Fukushima T.Environ Health Prev Med. 2005 Jan;10(1):3-8. doi: 10.1265/ehpm.10.3.Environ Health Prev Med. 2005.PMID:21432157Free PMC article.
References
- Hornykiewicz O. Clin Neurol Neurosurg. 1992;94:S9–S11. - PubMed
- Fahn S. Cecil’s Textbook of Medicine. Philadelphia: Saunders; 1988.
- Youdim M B, Riederer P. Sci Am. 1997;276:52–59. - PubMed
- Olanow C W. Trends Neurosci. 1993;16:439–444. - PubMed
- Forno L S, DeLanney L E, Irwin I, Langston J W. Adv Neurol. 1993;60:600–608. - PubMed
Publication types
MeSH terms
Substances
Related information
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources